TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Vaxart ( (VXRT) ).
Vaxart, Inc. faced a delisting from Nasdaq after failing to meet the conditions set by the Nasdaq Hearings Panel, which included obtaining shareholder approval and completing a reverse stock split by specified dates in 2025. Consequently, Vaxart’s common stock was suspended from trading on Nasdaq and is now quoted on the OTCQX Best Market under the symbol ‘VXRT’.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s stock score reflects strong revenue growth and promising vaccine developments, but is weighed down by profitability challenges, negative valuation metrics, and operational uncertainties.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Average Trading Volume: 1,878,368
Technical Sentiment Signal: Sell
Current Market Cap: $88.82M
For an in-depth examination of VXRT stock, go to TipRanks’ Overview page.